Merck & Company Inc (MRK)vsNutex Health Inc (NUTX)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NUTX
Nutex Health Inc
$200.24
+2.58%
HEALTHCARE · Cap: $1.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7762% more annual revenue ($66.57B vs $846.72M). NUTX leads profitability with a 21.2% profit margin vs 4.8%. NUTX trades at a lower P/E of 7.5x. NUTX earns a higher WallStSmart Score of 63/100 (C+).
MRK
Hold36
out of 100
Grade: F
NUTX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+61.7%
Fair Value
$269.07
Current Price
$200.24
$68.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 57.8%
Earnings expanding 95.9% YoY
Every $100 of equity generates 28 in profit
Keeps 21 of every $100 in revenue as profit
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Revenue declined 13.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NUTX
The primary concerns for NUTX are Market Cap, Revenue Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while NUTX is a declining play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.02 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NUTX scores higher overall (63/100 vs 36/100), backed by strong 21.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?